These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26102531)

  • 1. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
    Deenen MJ; de Kanter CT; Dofferhoff AS; Grintjes-Huisman KJ; van der Ven AJ; Fleuren HW; Gisolf EH; Koopmans PP; Drenth JP; Burger DM
    Ther Drug Monit; 2015 Dec; 37(6):751-5. PubMed ID: 26102531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
    Hatu G; Bailly F; Pourcelot E; Pradat P; Miailhes P; Maynard M; Parant F; Chiarello P; Livrozet JM; Zoulim F; Gagnieu MC
    BMC Infect Dis; 2014 Mar; 14():150. PubMed ID: 24650094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
    Piedoux S; Monnet E; Piroth L; Montange D; Royer B; Thevenot T; Kantelip JP; Di Martino V; Muret P;
    Antivir Ther; 2011; 16(8):1317-26. PubMed ID: 22155913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
    Lindahl K; Hörnfeld E; Ståhle L; Carlsson T; Weiland O; Parke Å; Schvarcz R
    Ther Drug Monit; 2015 Dec; 37(6):745-50. PubMed ID: 25811342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.
    Slim J; Mildvan D; Han J; Korner E
    J Int Assoc Provid AIDS Care; 2013; 12(5):354-62. PubMed ID: 23873217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
    Payer BA; Reiberger T; Breitenecker F; Aichelburg MC; Schuster C; Heil PM; Scherzer TM; Ferenci P; Rieger A; Peck-Radosavljevic M;
    J Infect; 2012 Aug; 65(2):142-9. PubMed ID: 22410384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
    Rallón NI; Pineda JA; Soriano V; Neukam K; Vispo E; Rivero A; Labarga P; Caruz A; Restrepo C; Camacho A; Barreiro P; Benito JM
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):117-23. PubMed ID: 22362153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
    Kennedy A; Hennessy M; Bergin C; Mulcahy F; Hopkins S; Spiers JP
    Antivir Ther; 2011; 16(8):1237-47. PubMed ID: 22155905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
    Bruno G; Saracino A; Fabrizio C; Scudeller L; Milano E; Dell'Acqua R; Ladisa N; Fasano M; Minniti S; Buccoliero G; Tartaglia A; Giammario A; Milella M; Angarano G
    Int J Antimicrob Agents; 2017 Mar; 49(3):296-301. PubMed ID: 28163136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
    Kheloufi F; Poizot-Martin I; Garraffo R; Tavenard A; Quaranta S; Renault A; Lavrut T; Bourlière M; Halfon P; Piroth L; Bellissant E; Lacarelle B; Molina JM; Solas C;
    Antivir Ther; 2017; 22(6):461-469. PubMed ID: 27583701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.
    Crespo M; Pou L; Esteban JI; Falcó V; Ribera E; Lopez R; Sauleda S; Curran A; Villar del Saz S; Feijoo M; Ocaña I; Pahissa A
    Antivir Ther; 2007; 12(8):1217-23. PubMed ID: 18240861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
    Solas C; Pambrun E; Winnock M; Salmon D; Poizot-Martin I; Dominguez S; Bani-Sadr F; Izopet J; Garraffo R; Peytavin G;
    AIDS; 2012 Nov; 26(17):2193-9. PubMed ID: 22781224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.